KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

NovoCure (NVCR) Operating Income (2016 - 2025)

NovoCure's Operating Income history spans 11 years, with the latest figure at -$40.4 million for Q4 2025.

  • For Q4 2025, Operating Income rose 36.19% year-over-year to -$40.4 million; the TTM value through Dec 2025 reached -$153.8 million, up 9.79%, while the annual FY2025 figure was -$153.8 million, 9.79% up from the prior year.
  • Operating Income for Q4 2025 was -$40.4 million at NovoCure, down from -$36.0 million in the prior quarter.
  • Across five years, Operating Income topped out at -$88000.0 in Q1 2021 and bottomed at -$63.3 million in Q4 2024.
  • The 5-year median for Operating Income is -$36.9 million (2025), against an average of -$34.6 million.
  • The largest annual shift saw Operating Income skyrocketed 97.4% in 2021 before it crashed 7375.06% in 2023.
  • A 5-year view of Operating Income shows it stood at -$23.4 million in 2021, then crashed by 83.68% to -$43.0 million in 2022, then dropped by 20.33% to -$51.7 million in 2023, then dropped by 22.41% to -$63.3 million in 2024, then skyrocketed by 36.19% to -$40.4 million in 2025.
  • Per Business Quant, the three most recent readings for NVCR's Operating Income are -$40.4 million (Q4 2025), -$36.0 million (Q3 2025), and -$39.5 million (Q2 2025).